Blog

  1. Reporting from Alpbach – three ways to validate antibodies

    Last week our founder Dr Andrew Chalmers was in Alpbach for the 8th Affinity Proteomics Meeting, where he presented CiteAb’s latest antibody validation efforts. At the event a huge range of antibody and proteomics science was presented, ranging from exciting new new binders to antibody engineering and therapeutics. Andrew said: “Over the course of the […]

  2. We’re recruiting! Graduate developer wanted to join our team.

        THE DEADLINE FOR APPLICATIONS HAS NOW CLOSED     Here at CiteAb we’re looking for a graduate in Computer Science to join our team and help to develop our industry leading data curation, machine learning and search engine technology. Job title: Graduate Developer Location: Bath Salary: Starting £22 – £27k Hours: Full Time. Part […]

  3. We’re recruiting! Biologist or Chemist wanted to join our team.

        THE DEADLINE FOR APPLICATIONS HAS NOW CLOSED     Here at CiteAb we’re looking for a graduate in biological sciences or chemistry to join our team and manage some of our key data products. Job title: Data product manager (Biological Sciences or Chemistry) Location: Bath Salary: Competitive (Based on qualifications and experience) Hours: Full […]

  4. Winner profile: custom antibody or alternative affinity reagent supplier

    We recently announced the winners of the 2017 CiteAb Antibody Awards, and today we feature the winner profile here on our blog for the category of ‘Custom antibody or alternative affinity reagent supplier 2017’. The winners of this category for 2017 are Bio-Rad, headquartered in California, USA, and trading internationally. This category recognises a supplier […]

  5. Winner profile: Antibody Validation Initiative 2017

    We recently announced the winners of the 2017 CiteAb Antibody Awards, and today we feature the winner profile here on our blog for the prestigious category of ‘Most Exciting Antibody Validation Initiative 2017’. The winners of this category for 2017 are Abcam, headquartered in the UK and trading internationally. This category was extremely competitive and […]

  6. Winner profile: Researchers’ Choice award 2017

    We recently announced the winners of the 2017 CiteAb Antibody Awards, and today we feature our first winner profile here on our blog for the prestigious category of ‘Researchers’ Choice’. The winners of this category for 2017 are Cell Signaling Technology, headquartered in the USA and trading internationally. The Researchers’ Choice award is of specific […]

  7. Monoclonals take pole position

    For the first time in 42 years, use of monoclonal antibodies has overtaken polyclonals in the research antibody market. Production of monoclonal antibodies was first described by Georges Köhler and César Milstein in 1975, and the pair were awarded the Nobel Prize in 1984. Monoclonal antibodies then became the dominant antibodies used in therapeutic and […]

  8. Announcing the winning ‘Researchers’ Choice’ nominator

    This year, as part of the CiteAb Antibody Awards, we offered researchers the chance to be entered into a prize draw for nominating their favourite antibody suppliers. This category had a large number of entries this year, and we selected the prize-winning nominator at random. Congratulations to Netanya Spencer of the Joslin Diabetes Center at Harvard […]

  9. CiteAb 2017 Antibody Awards update

    Thank you all for making this years awards more exciting than ever before – we’ve had a huge number of entries which our judges are now going through. We’re also scrutinising CiteAb data to establish winners for the data-driven categories. Award winners will be announced here on our blog on Monday 30th January at midday, […]

  10. What are the most used protein targets for ChIP?

    Our latest data set outlines the protein targets most used for Chromatin Immunoprecipitation (ChIP) – it was created by our team looking specifically at antibody citations over the past ten years that carried out ChIP and working out what the most commonly used protein targets for the antibodies were. Dr Andrew Chalmers, founder of CiteAb, […]